SCHEMBL2483009

SCHEMBL2483009

O=C(O)c1ccccc1Oc1cccc(I)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTNNB1 P35222 1/20 0.51
KDM4E B2RXH2 4/20 0.51
POLB P06746 1/20 0.51
HTT P42858 1/20 0.50
ALDH1A1 P00352 3/20 0.49
AKR1C3 P42330 1/20 0.49
F7 P08709 1/20 0.46
F3 P13726 1/20 0.46
PYGM P11217 4/20 0.46
PYGL P06737 3/20 0.45
HPGD P15428 3/20 0.45
HSD17B10 Q99714 3/20 0.45
ESR1 P03372 1/20 0.45
ITGB3 P05106 1/20 0.45
ITGA2B P08514 1/20 0.45
HMGB1 P09429 1/20 0.45
TSHR P16473 1/20 0.45
GGT1 P19440 1/20 0.45
PTGS1 P23219 1/20 0.45
PTGS2 P35354 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3842596 0.89 CTNNB1 (0.49) CTNNB1KDM4EPOLBALDH1A1AKR1C3
SCHEMBL28560551 0.88 KDM4E (0.63) CTNNB1KDM4EPOLBHTTALDH1A1
SCHEMBL7457156 0.88 CTNNB1 (0.49) CTNNB1KDM4EPOLBAKR1C3PYGM
SCHEMBL28264707 0.86 KDM4E (0.61) CTNNB1KDM4EPOLBHTTALDH1A1
SCHEMBL921873 0.85 AKR1C3 (0.69) CTNNB1KDM4EPOLBHTTALDH1A1
SCHEMBL1798 0.82 CTNNB1 (0.71) CTNNB1KDM4EHTTALDH1A1HPGD
SCHEMBL742799 0.82 CTNNB1 (0.53) CTNNB1KDM4EPOLBHTTALDH1A1
SCHEMBL30975119 0.82 CTNNB1 (0.53) CTNNB1KDM4EPOLBHTTALDH1A1
SCHEMBL24407810 0.81 CTNNB1 (0.56) CTNNB1KDM4EPOLBHTTALDH1A1
SCHEMBL15304483 0.81 AKR1C3 (0.54) CTNNB1KDM4EPOLBHTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021003295-A1 MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF REGENERON PHARMACEUTICALS, INC. (US) 2021-01-07 WO disclosed
EP-2376197-A2 APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES Abbott Laboratories (US) 2011-10-19 EP disclosed